Exploring Advancements in the Treatment of Non–Small Cell Lung Cancer with EGFR Alterations

A panel of medical oncologists introduce themselves and provide clinical insights on biomarker testing practices for patients with non–small cell lung cancer.

The discussion on biomarker testing practices for patients with non–small cell lung cancer turns its focus to the metastatic setting.

Expert perspectives on next-generation sequencing for patients with non–small cell lung cancer, highlighting challenges and the differences between RNA and DNA testing.

An overview of frontline treatment options for patients with EGFR-mutated non–small cell lung cancer.

Medical oncologists review the FLAURA2 study looking at osimertinib with or without chemotherapy in EGFR-mutated NSCLC and discuss patients for whom they would consider the therapy.

Focusing on the MARIPOSA trial, the panel provides thoughts the potential role of amivantamab and lazertinib, and discusses treatment decisions upon progression.

Following a review of the MARIPOSA-2 trial, experts on non–small cell lung cancer discuss treatment approaches in the second line.

An overview of the treatment landscape for patients with non–small cell lung cancer with EGFR exon 20 insertion mutations.

Medical oncologists review updated data from the PAPILLON trial on amivantamab plus chemotherapy and discuss the treatment of patients with NSCLC with EGFR exon 20 insertions.

The expert panel concludes with thoughts on unmet needs and future perspectives on the treatment of patients with EGFR-mutated non–small cell lung cancer.

A recent Training Academy focused on the advancements of treatment for patients with NSCLC EGFR mutations and exon 20 insertions.